News and Trends 25 May 2023 PharmEnable raises $7.5M to develop small molecule drugs to treat cancer and neurological diseases PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi […] May 25, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 New epilepsy study could lead to new treatment options The mechanisms underlying the pathogenesis of epilepsy, a neurological disorder characterized by excessive electrical activity in the brain, remain unknown. Now, using a novel radiotracer, researchers from Japan have been able to offer insight into the role of AMPAR trafficking in epileptogenesis. The radio tracer is [11C]K-2, the first technology to visualize and quantify α-amino-3-hydroxy-5-methyl-4-isoxazole […] May 18, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Sania Therapeutics launches to advance neural circuit dysfunction medicines Sania Therapeutics, which develops genetic medicines for neural circuit dysfunction, has launched with the unveiling of its platforms at the American Society of Gene & Cell Therapy (ASGCT) conference. Sania Therapeutics’ approach combines the evolution of adeno-associated viruses (AAV) in human neural circuits, the fundamental components of the nervous system, and tuneable conditionally-activated ion channels. […] May 18, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Business France 20 Apr 2023 8 life science innovators you must meet at BioTrinity 2023 April 20, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Noema Pharma raises $112 million in Series B financing Noema Pharma, a Swiss clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, has closed an oversubscribed Series B financing round, raising CHF 103 million ($112 million) from new and existing investors. The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor […] March 8, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 Biocytogen launches nanobody therapeutics project for 100 targets Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has launched the “Nano 100 Project,” which aims to develop fully human nanobody drugs for more than 100 targets. The project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale. Compared […] February 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 Sysnav and Roche partner on movement tracking technology Sysnav Healthcare and Roche have partnered to develop industry standard outcome measurements in diseases associated with movement impairments, as well as designing the next generation of wearable technology based on Sysnav’s technology. Patients living with a neuromuscular disorder often suffer from movement impairments that fundamentally impact their daily life. Reliable, objective measurements of a patient’s […] January 26, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 Funding for university to develop new motor neuron disease therapies Medical research charity LifeArc, the Motor Neurone Disease Association (MND Association) and the My Name’5 Doddie Foundation have jointly awarded £1 million ($1.2 million) to researchers at University College London (UCL) to progress two pioneering new therapies that could help transform the lives of those living with motor neuron disease (MND). The research grants are […] January 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Team wins $149M contract for National Institute of Neurological Disorders and Stroke A team consisting of Battelle, AmplifyBio and Andelyn Biosciences has won a seat on an eight-year, $149 million indefinite delivery, indefinite quantity (IDIQ) contract vehicle for the National Institute of Neurological Disorders and Stroke in the U.S. As one of the prime contractors on the multi-award IDIQ, the team will provide manufacturing and nonclinical support […] January 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Silo Pharma looks into the 2023 psychedelics crystal ball Labiotech had the opportunity to ask James Kuo, vice president of R&D at Silo Pharma Inc., about his predictions for the field of psychedelic research in 2023. Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare […] January 11, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 STALICLA signs agreement with Novartis on neurodevelopmental disorders STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs). Mavoglurant has previously been tested in more than 1,800 patients and demonstrated a good safety and […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: IRLAB CEO Richard Godfrey IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson’s disease. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to […] December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email